Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.15), Zacks reports.
Artiva Biotherapeutics Price Performance
NASDAQ:ARTV traded down $0.04 on Tuesday, reaching $2.06. The stock had a trading volume of 52,651 shares, compared to its average volume of 174,109. Artiva Biotherapeutics has a 12-month low of $1.78 and a 12-month high of $17.31. The firm's fifty day moving average is $3.15 and its two-hundred day moving average is $6.76.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. Cantor Fitzgerald decreased their price target on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a research note on Tuesday, March 25th. Wedbush reissued an "outperform" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a report on Tuesday, March 25th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Artiva Biotherapeutics in a report on Wednesday, March 26th. Finally, Needham & Company LLC restated a "buy" rating and set a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday, April 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $20.40.
Get Our Latest Stock Report on Artiva Biotherapeutics
Artiva Biotherapeutics Company Profile
(
Get Free Report)
Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
Read More
Before you consider Artiva Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artiva Biotherapeutics wasn't on the list.
While Artiva Biotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
